Abstract
Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials. Methods We searched for ADNI publications using established methods. Results ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis. Discussion ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 865-884 |
| Number of pages | 20 |
| Journal | Alzheimer's and Dementia |
| Volume | 11 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 1 2015 |
Fingerprint
Keywords
- AD biomarker signature
- Alzheimer's disease
- Amyloid phenotyping
- Clinical trial biomarkers
- Data-sharing
- Tau imaging
- Worldwide ADNI
ASJC Scopus subject areas
- Clinical Neurology
- Developmental Neuroscience
- Cellular and Molecular Neuroscience
- Psychiatry and Mental health
- Geriatrics and Gerontology
- Epidemiology
- Health Policy
Cite this
Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. / Weiner, Michael W.; Veitch, Dallas P.; Aisen, Paul S.; Beckett, Laurel A.; Cairns, Nigel J.; Cedarbaum, Jesse; Donohue, Michael C.; Green, Robert C.; Harvey, Danielle; Jack, Clifford R Jr.; Jagust, William; Morris, John C.; Petersen, Ronald Carl; Saykin, Andrew J.; Shaw, Leslie; Thompson, Paul M.; Toga, Arthur W.; Trojanowski, John Q.
In: Alzheimer's and Dementia, Vol. 11, No. 7, 01.07.2015, p. 865-884.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014
AU - Weiner, Michael W.
AU - Veitch, Dallas P.
AU - Aisen, Paul S.
AU - Beckett, Laurel A.
AU - Cairns, Nigel J.
AU - Cedarbaum, Jesse
AU - Donohue, Michael C.
AU - Green, Robert C.
AU - Harvey, Danielle
AU - Jack, Clifford R Jr.
AU - Jagust, William
AU - Morris, John C.
AU - Petersen, Ronald Carl
AU - Saykin, Andrew J.
AU - Shaw, Leslie
AU - Thompson, Paul M.
AU - Toga, Arthur W.
AU - Trojanowski, John Q.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials. Methods We searched for ADNI publications using established methods. Results ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis. Discussion ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.
AB - Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials. Methods We searched for ADNI publications using established methods. Results ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis. Discussion ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.
KW - AD biomarker signature
KW - Alzheimer's disease
KW - Amyloid phenotyping
KW - Clinical trial biomarkers
KW - Data-sharing
KW - Tau imaging
KW - Worldwide ADNI
UR - http://www.scopus.com/inward/record.url?scp=84937573808&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84937573808&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2015.04.005
DO - 10.1016/j.jalz.2015.04.005
M3 - Article
VL - 11
SP - 865
EP - 884
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
SN - 1552-5260
IS - 7
ER -